Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 25:14:1167975.
doi: 10.3389/fimmu.2023.1167975. eCollection 2023.

Immune-related adverse events of immune checkpoint inhibitors: a review

Qinan Yin  1   2 , Liuyun Wu  1   2 , Lizhu Han  1   2 , Xingyue Zheng  1   2 , Rongsheng Tong  1   2 , Lian Li  1   2 , Lan Bai  1   2 , Yuan Bian  1   2
Affiliations
Review

Immune-related adverse events of immune checkpoint inhibitors: a review

Qinan Yin et al. Front Immunol. .

Abstract

Since the first Immune Checkpoint Inhibitor was developed, tumor immunotherapy has entered a new era, and the response rate and survival rate of many cancers have also been improved. Despite the success of immune checkpoint inhibitors, resistance limits the number of patients who can achieve a lasting response, and immune-related adverse events complicate treatment. The mechanism of immune-related adverse events (irAEs) is unclear. We summarize and discuss the mechanisms of action of immune checkpoint inhibitors, the different types of immune-related adverse events and their possible mechanisms, and describe possible strategies and targets for prevention and therapeutic interventions to mitigate them.

Keywords: epidemiology; immune checkpoint inhibitors; immune-related adverse events; management; mechanism.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The Action Mechanisms of Immune Checkpoints.
Figure 2
Figure 2
The potential adverse effect mechanisms of immune checkpoint inhibitors.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. with a report of ten original cases. 1893. Clin Orthop Relat Res (1991) 1991(262):3–11. - PubMed
    1. Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol (2021) 16:223–49. doi: 10.1146/annurev-pathol-042020-042741 - DOI - PubMed
    1. Wood LS, Moldawer NP, Lewis C. Immune checkpoint inhibitor therapy: key principles when educating patients. Clin J Oncol Nurs (2019) 23:271–80. doi: 10.1188/19.CJON.271-280 - DOI - PubMed
    1. Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chavez A, Keegan N, Khamashta MA, et al. . Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers (2020) 6:38. doi: 10.1038/s41572-020-0160-6 - DOI - PMC - PubMed
    1. Li B, Chan HL, Chen P. Immune checkpoint inhibitors: basics and challenges. Curr Med Chem (2019) 26:3009–25. doi: 10.2174/0929867324666170804143706 - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources